Fulgent Genetics, Inc. (FLGT) Financial Statements
Industry: Medical Laboratories (Services)
In fiscal 2025, Fulgent Genetics reported revenue of $322.7M, up 13.8% from $283.5M the year before. Net income was -$60.5M (a -18.8% net margin), or -$1.97 per diluted share. Gross margin was 40.6% and operating margin was -28.2%. Operating activities generated -$101.6M of cash, leaving -$124.2M of free cash flow. At fiscal year end, Fulgent Genetics held $1.21B in total assets against $106.8M in total liabilities, including $50.2M of cash and equivalents.
Open the full interactive Fulgent Genetics financials → Quarterly statements, key ratios, valuation history and price charts.
Fulgent Genetics Key Stats
| Share Price | $21.06 |
|---|---|
| Market Cap | $589.8M |
| Revenue YoY Growth | +13.8% |
| 52-Week Range | $13.79 – $30.85 |
| Shares Outstanding | 28.0 million (basic, 2026 Q2) |
Fulgent Genetics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $421.7M | $992.6M | $619.0M | $289.2M | $283.5M | $322.7M |
| Gross Profit | $331.9M | $777.1M | $366.9M | $104.5M | $107.2M | $130.9M |
| Operating Income | $290.2M | $676.0M | $178.5M | -$195.5M | -$73.9M | -$91.1M |
| Pre-Tax Income | $291.7M | $677.3M | $184.0M | -$174.1M | -$52.0M | -$70.0M |
| Income Tax | $72.5M | $174.8M | $42.1M | $1.2M | -$8.1M | -$8.4M |
| Net Income | $214.3M | $507.4M | $143.4M | -$167.8M | -$42.7M | -$60.5M |
| Diluted EPS | $8.91 | $16.38 | $4.63 | -$5.63 | -$1.41 | -$1.97 |
Fulgent Genetics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $84.1M | $83.3M | $71.1M | $85.4M |
| Net Income | -$6.6M | -$23.4M | -$24.8M | -$29.5M |
| Diluted EPS | -$0.21 | -$0.76 | -$0.80 | -$1.05 |
Fulgent Genetics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $87.4M | $164.9M | $79.5M | $97.5M | $55.1M | $50.2M |
| Current Assets | $523.6M | $612.0M | $627.9M | $507.8M | $353.6M | $550.5M |
| Total Assets | $700.5M | $1.28B | $1.39B | $1.24B | $1.22B | $1.21B |
| Current Liabilities | $130.1M | $105.3M | $88.1M | $73.0M | $72.9M | $85.0M |
| Total Long-Term Debt | — | — | — | $4.1M | $2.9M | $2.4M |
| Total Liabilities | $131.1M | $112.8M | $116.2M | $102.0M | $90.8M | $106.8M |
| Shareholders' Equity | $569.4M | $1.16B | $1.27B | $1.14B | $1.13B | $1.11B |
Fulgent Genetics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $140.6M | $538.6M | $253.5M | $27.0M | $21.1M | -$101.6M |
| Cash From Investing | -$326.4M | -$546.5M | -$261.3M | $38.9M | -$58.4M | $111.4M |
| Cash From Financing | $261.3M | $85.4M | -$77.1M | -$47.8M | -$4.8M | -$14.8M |
| Free Cash Flow | $105.5M | $514.8M | $234.7M | $4.8M | -$19.3M | -$124.2M |
Figures from Fulgent Genetics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Fulgent Genetics financials page for every line item.
Fulgent Genetics Company Profile
| Ticker | FLGT |
|---|---|
| Exchange | Nasdaq |
| Industry | Medical Laboratories (Services) |
| Headquarters | El Monte, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001674930 |
Frequently Asked Questions
What was Fulgent Genetics' revenue in fiscal 2025?
Fulgent Genetics (FLGT) reported revenue of $322.7M for fiscal 2025.
What is Fulgent Genetics' annual revenue history?
Fulgent Genetics' annual revenue by fiscal year: 2020: $421.7M; 2021: $992.6M; 2022: $619.0M; 2023: $289.2M; 2024: $283.5M; 2025: $322.7M.
What was Fulgent Genetics' net income in fiscal 2025?
Fulgent Genetics reported net income of -$60.5M for fiscal 2025.
What was Fulgent Genetics' earnings per share (EPS) in fiscal 2025?
Fulgent Genetics' diluted EPS was -$1.97 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Fulgent Genetics generate in fiscal 2025?
Fulgent Genetics generated -$124.2M of free cash flow in fiscal 2025.
What was Fulgent Genetics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Fulgent Genetics reported revenue of $85.4M.
How much debt does Fulgent Genetics have?
Fulgent Genetics reported $2.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Fulgent Genetics are outstanding?
Fulgent Genetics reported a weighted average of 28.0 million basic shares outstanding in 2026 Q2.
What is Fulgent Genetics' market cap?
Based on its latest closing price, Fulgent Genetics (FLGT) has a market capitalization of about $589.8M.
When does Fulgent Genetics' fiscal year end?
Fulgent Genetics' fiscal year end, as registered with the SEC, is December 31.
Where is Fulgent Genetics headquartered?
Fulgent Genetics lists its business address in El Monte, California in its SEC filings.